Optimizing the expediency of TNFi in rheumatoid arthritis: Offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase

Expert Opinion on Biological Therapy

Volumn 14, Issue 12, 2014, Pages 1761-1767

  Van Ingen, Iris L A ^a   Lamers Karnebeek, Femke ^a   Jansen, Tim L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biological disease modifying antirheumatic drugs; Rheumatoid arthritis; TNFi; Tnf

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PROTEIN S 100; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; DAS28; DECISION MAKING; DISEASE ACTIVITY; DISEASE DURATION; DRUG EXPOSURE; DRUG SAFETY; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; LOW DISEASE ACTIVITY; MAINTENANCE THERAPY; MONOTHERAPY; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DISEASE COURSE; DRUG ADMINISTRATION; MINIMAL RESIDUAL DISEASE; PROCEDURES; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; METHOTREXATE; NEOPLASM, RESIDUAL; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84910026198     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.955009     Document Type: Review

References (42)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27(2):269-81
2. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs. Ann Rheum Dis 2010;69(6):964-75
3. Furneri G, Mantovani LG, Belisari A, et al. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(4 Suppl 73):S72-84
4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365(23):2205-19
5. Nell VPK, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43(7):906-14
6. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50(7):2072-81
7. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19(1):163-77
8. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66(1):34-45
9. Smolen JS, Landewe R, Breeveld CR, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013
10. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69(4):631-7
11. O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010;69(10):1823-6
12. Scott IC, Kingsley GH, Scott DL. Can we discontinue synthetic diseasemodifying anti-rheumatic drugs in rheumatoid arthritis? Clin Exp Rheumatol 2013;31(4 Suppl 78):S4-8
13. Allaart CF, Lems WF, Huizinga TW. The BeSt way of withdrawing biologic agents. Clin Exp Rheumatol 2013;31(4 Suppl 78):S14-18
14. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86
15. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337(3):141-7
16. Pavelka K, Szekanecz Z, Damjanov N, et al. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clin Rheumatol 2013;32(9):1275-81
17. Villeneuve E, Nam JL, Hensor E, et al. Preliminary results of a MULTICENTRE randomised controlled trial of etanercept and methotrexate to induce remission in patients with newly diagnosed inflammatory arthritis. Arthritis Rheum 2011;63(Suppl 10):2465
18. Emery P. Impact of etanerceptmethotrexate therapy on patient-reported outcomes in rheumatoid arthritis patients with up to 12 months of symptoms [abstract]. Arthritis Rheum 2011;64:S160
19. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381(9870):918-29
20. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48(1):35-45
21. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebocontrolled, 52-week trial. Arthritis Rheum 2004;50(5):1400-11
22. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54(1):26-37
23. Smolen JS, Emery P, Fleischmann R, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383(9914):321-32
24. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72(6):844-50
25. Hirata S, Saito K, Kubo S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther 2013;15(5):R135
26. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68(6):805-11
27. Weinblatt ME, Fleischmann R, Huizinga TW, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford) 2012;51(12):2204-14
28. Smolen JS, Emery P, Ferraccioli G, et al. Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdraw of certolizumab pegol treatment: week 52 results from the CERTAIN study. Ann Rheum Dis 2012;71(Suppl 3):361
29. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52(1):27-35
30. Klarenbeek NB, van der Kooij SM, Güler-Yüksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011;70(2):315-19
31. Nam JL, Villeneuve E, Hensor EMA, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 2014;73(1):75-85
32. van der Maas A, Kievit W, van den Bemt BJ, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis 2012;71(11):1849-54
33. Alten R, Pohl C, Choy EH, et al. Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA flare definition working group. J Rheumatol 2011;38(8):1745-50
34. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69(7):1286-91
35. Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69(9):1636-42
36. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76(4):350-5
37. Lamers-Karnebeek FBG, Jacobs JW, Fransen J, et al. The Poet-US study: can ultrasonography predict flare in patients with RA and persistent low disease activity in whom the TNF inhibitor is stopped? preliminary results of an ongoing study. Ann Rheum Dis 2013;72:214
38. Yoshida K, Radner H, Kavanaugh A, et al. Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clin Exp Rheumatol 2013;31(4 Suppl 78):S28-32
39. Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3112
40. den Broeder AA, van Herwaarden N, van der Maas A, et al. Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord 2013;14:299
41. Fautrel B, Pham T, Morel J, et al. Results of the strass trial regarding impact of progressive spacing of Tnfblocker injections in rheumatoid arthritis patients in Das28 remission: is there a difference between drugs - adalimumab and etanercept - or their mode of use - monotherapy or combination? [abstract]. Arthritis Rheum 2013;65(Suppl 10):2691
42. Tanaka Y. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis 2013;72(Suppl 2):124-7, doi: 10.1136/annrheumdis-2012-202350